Metrion Biosciences (“Metrion”), the specialist preclinical contract analysis group (CRO) and a pacesetter in ion channel screening, immediately introduced the appointment of Lee Patterson as its new CEO, efficient from 2nd December 2024. An skilled life sciences and CRO govt, Lee will information the Firm because it seeks to execute an bold development technique, enhancing its specialist companies and increasing additional in key world markets. He succeeds Dr Andrew Southan, who has determined to step down as CEO after 5 years within the publish.
A famend chief within the sector, Lee Patterson makes a speciality of steering preclinical CROs to implement sturdy and efficient plans for long-term industrial development. Beforehand CEO at Charnwood Discovery, a supplier of built-in drug discovery companies with a worldwide biotech and pharma shopper base, he led the corporate by means of its profitable acquisition by Idea Life Sciences in October 2024. Previous to this, Lee served as Chief Working Officer at Quanticate, a worldwide biometrics CRO, and Chief Working Officer at Idea Life Sciences. He additionally held a number of govt roles at Covance/Labcorp, the newest being Govt Director, World Operations and Early Improvement Administration Workplace.
Lee will be a part of not too long ago appointed CCO Dr Chris Mathes as the most recent addition to Metrion’s senior management crew1. Working carefully alongside Chris and the broader administration crew, Lee’s C-suite stage experience and expertise will help Metrion to bolster its world industrial presence and scientific capabilities.
Outgoing CEO Dr Andrew Southan has led Metrion efficiently since 2019, greater than doubling revenues over that point and overseeing the Firm’s development in staffing, laboratory services and worldwide shopper base. He additionally led the Firm’s profitable £3.7M fairness financing spherical in December 2023.
On behalf of the Board and administration crew, I wish to thank Andy Southan for his devoted management over the past 5 years, particularly establishing Metrion’s status as a top quality, specialist CRO and a number one middle of experience in ion channel biology. On the identical time, I’m delighted to welcome Lee Patterson to the Firm. His expertise of main industrial CROs and his experience in enhancing operational efficiencies are each excellent and we sit up for working with him to proceed Metrion’s development as a specialist CRO serving world markets.”
Keith McCullagh, Chairman, Metrion Biosciences
Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has constructed a powerful status in ion channel drug discovery, with confirmed dedication to excellent customer support and world class science. I’m excited to hitch this gifted crew and sit up for working with them to reinforce and broaden our specialised companies to satisfy the wants of our purchasers worldwide.”